- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Axplora invests Euro 6.5 million to expand production capacity at Vizag site

Axplora has announced a significant investment at its Vizag site in India to expand production capacity and reinforce supply chain resilience. This announcement follows the successful completion of routine USFDA inspections in 2025 at both of Axplora’s Indian manufacturing sites, Vizag and Chennai, which form part of the company’s PharmaZell Business Unit.
The expansion project at Vizag will increase output and create new employment opportunities.
"The investment also advances the company’s sustainability goals by supporting efficient, vertically integrated production at a single site," the release stated.
“This investment reflects Axplora’s strategic commitment to operational excellence and customer- centric growth,” said Martin Meeson, CEO of Axplora. “By strengthening our infrastructure in Vizag, we are enhancing our ability to deliver high-quality, reliable, and scalable solutions to customers worldwide.”
Both the Vizag and Chennai sites successfully completed routine inspections by the US Food and Drug Administration (USFDA) in 2025, each concluding with a Voluntary Action Indicated (VAI) classification.
As per the release, the inspector at the Chennai facility highlighted several areas of excellence, including the strong and consistent implementation of current Good Manufacturing Practices (cGMP), streamlined and efficient document management and retrieval processes, and the high standards maintained in facility upkeep and overall site hygiene.
“These results are a powerful validation of our team’s diligence and our unwavering focus on quality.” said Anant Barbadikar, Co-President of PharmaZell and Chief Operating Officer in India. “The success of both inspections reflects not just regulatory compliance, but the operational integrity and continuous improvement culture we strive to embed across every Axplora site.”
Axplora is a manufacturing partner to over 900 of the world’s pharmaceutical and biotech companies, formed from the integration of PharmaZell, Farmabios, and Novasep CDMO.
Axplora supports pharmaceutical and biotech companies in developing and producing life-changing therapies. Axplora operates 9 API manufacturing sites across Europe and India, providing multi-site capacity to partners worldwide.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751